283153-83-3

Basic information

• Product Name: Acetic acid, [(4-bromophenyl)thio]-, 1,1-dimethylethyl ester
• CAS NO: 283153-83-3
• Molecular Formula: C12H15BrO2S
• Molecular Weight: 303.22
• Mol File: 283153-83-3.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: Acetic acid, [(4-bromophenyl)thio]-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Acetic acid, [(4-bromophenyl)thio]-, 1,1-dimethylethyl ester(283153-83-3)
• EPA Substance Registry System: Acetic acid, [(4-bromophenyl)thio]-, 1,1-dimethylethyl ester(283153-83-3)

Safety Data

• Hazardous Substances Data: 283153-83-3(Hazardous Substances Data)

Upstream product

• 5292-43-3 bromoacetic acid tert-butyl ester 
• 106-53-6 para-bromobenzenethiol 

Downstream Products

• 476193-19-8 tert-butyl 2-((4-bromophenyl)sulfonyl)acetate 
• 283153-84-4 ethyl 4-[[(t-butoxycarbonyl)methyl]thio]cinnamate 

Relevant articles and documents

ION PAIR CATALYSIS OF TUNGSTATE AND MOLYBDATE

D The present invention relates to ion pair catalysts (I) comprising the cationic bisguanidinium ligand (A) and diperoxomolybdate anion (B). The present invention also relates to ion pair catalysts (III) comprising the cationic bisguanidinium ligand (C) and peroxotungstate anion (D). It further relates to the use of the said catalysts in the manufacture of enantiomerically enriched sulfoxides.

Discovery of Small-Molecule Inhibitors of the ATPase Activity of Human Papillomavirus E1 Helicase

The Boehringer Ingelheim compound collection was screened for inhibitors of the ATPase activity of human papillomavirus E1 helicase to develop antiviral agents that inhibit human papillomavirus (HPV) DNA replication. This screen led to the discovery of (biphenyl-4-sulfonyl)acetic acid 1, which inhibits the ATPase activity of HPV type 6 E1 helicase with a low micromolar IC50 value. A hit-to-lead exercise rapidly converted 1 into a low nanomolar lead series.

Cinnamamide derivatives and drug compositions containing the same

The invention relates to cinnamamide derivatives having the following formula wherein R1represents a hydroxyl group, a C1-6-alkoxy group, an arylalkoxy group or a substituted or unsubstituted amino group; R2and R3are same or different, each of which represents a hydrogen atom, a halogen atom or a C1-4-alkyl group; R4represents a hydrogen atom or a C1-6-alkyl group; R5represents a hydrogen atom, a C1-6-alkyl group or an aryl group; R6represents a hydrogen atom, a C1-6-alkyl group, a cyano group or a C1-6-alkoxy-carbonyl group; W represents an oxygen atom, a sulfur atom, an imino group, a methylene group, a hydroxymethylene group or a carbonyl group; X and Y are same or different, each of which represents an oxygen atom or a sulfur atom; m represents an integer of 0 to 2; n represents an integer of 1 to 3; and when m is 0, a group: —C(R2)(R3)—W— may represent a vinylene group; or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition containing the above compound, in particular, an immunomodulatory agent and a prophylactic or therapeutic agent for nephrotic syndrome, circulatory disorders or respiratory diseases.